

GP1814

756

4155-102US

IG4-9.2FWC

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on December 27, 1996.



[Signature]
Bruce M. Collins

RECEIVED

JAN 15 1997

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

JUN 3 1997

BOARD OF PATENT APPEALS
AND INTERFERENCES

In re Application of
GREGORY *et al.*

Serial No. 08/087,132

Filed: July 2, 1993

For: NEW DIAGNOSTIC AND
TREATMENT METHODS
INVOLVING THE CYSTIC
FIBROSIS TRANSMEMBRANE
REGULATOR

Group Art Unit: 1814
Examiner: K.C. Carlson, Ph.D.

Assistant Commissioner for Patents
Washington, D. C. 20231

SIR:

**SUPPLEMENTAL AMENDMENT
AND
REQUEST FOR INTERFERENCE UNDER 37 CFR §1.607**

Further to Applicants' Response of August 6, 1996, kindly amend this application as follows:

Add new claims 226 and 227 reading as follows:

-- 226. A recombinant vector comprising a DNA regulatory element operably linked to a DNA molecule that encodes a wild-type, human cystic fibrosis transmembrane conductance regulator protein, wherein the DNA molecule is capable of stable propagation in *E. coli*. --